Phio Pharmaceuticals (PHIO)
(Delayed Data from NSDQ)
$3.35 USD
-0.07 (-2.04%)
Updated Sep 25, 2024 03:59 PM ET
After-Market: $3.35 0.00 (0.00%) 6:24 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Phio Pharmaceuticals Corp. [PHIO]
Reports for Purchase
Showing records 1 - 20 ( 27 total )
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
1Q24 Results: Looking for PH-762 Clinical Momentum to Continue; Reiterate Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
Modified siRNA for a Bargain; Reiterate Buy Rating With PT Adjusted Down to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
FDA Clearance of PH-762 Studies Marks a Major Milestone; Reiterate Buy Rating and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
FDA Approves Phase 1 Clinical Trial of PH-762 and AGX148 in Advanced Solid Tumors; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
New Clinical Program of PH-762 in Cutaneous Squamous Cell Carcinoma; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
INTASYL Continues to Make Progress; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
Preclinical Results Show PH-762 Prolongs T Cell Tumor-Killing Activity; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
INTASYL Pipeline Continues to Make Progress; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
PH-894 Demonstrates Potential as Monotherapy in PD-1 Refractory Disease Models at AACR; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
Moving Towards Initiation of First-In-Human INTASYL Studies; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
INTASYL Product Candidates Set to Enter Further Clinical Testing; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
PH-762 on Track for First-in-Human Clinical Trial in Advanced Melanoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
INTASYL Data Gathering Strength and Generating Interest; Reit Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
The Clinic is Ready to See INTASYL Now; Reiterate Buy and Raise PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
Expect Year-End Momentum to Move INTASYL Compounds Into Clinical Phase in 2021; Reiterate Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
Data at SITC Show Combination Intratumoral Treatment With INTASYL Improves Tumor Control; Reiterate Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Phio Pharmaceuticals Corp.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department